Agios’ oral drug se­cures PhI­II suc­cess in trans­fu­sion-in­de­pen­dent tha­lassemia pa­tients

Agios Phar­ma­ceu­ti­cals’ oral drug can­di­date is a step clos­er to mar­ket af­ter it suc­ceed­ed in a late-stage study in tha­lassemia pa­tients who don’t need reg­u­lar trans­fu­sions. The com­pa­ny is now gear­ing up for reg­u­la­to­ry ac­tiv­i­ties by year’s end.

The Phase III EN­ER­GIZE tri­al in­ves­ti­gat­ed the pyru­vate ki­nase ac­ti­va­tor mi­tapi­vat ver­sus place­bo in 194 sub­jects with non-trans­fu­sion-de­pen­dent al­pha- or be­ta-tha­lassemia.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER